Status:

WITHDRAWN

Evaluation and Adverse Event Surveillance for Initial Implementation of ShangRing Circumcision in Mozambique

Lead Sponsor:

Jhpiego

Collaborating Sponsors:

Ministry of Health, Mozambique

Centers for Disease Control and Prevention

Conditions:

Circumcision, Male

Eligibility:

MALE

13+ years

Phase:

NA

Brief Summary

This is a single-arm interventional study of 1000 male circumcision procedures using the ShangRing device. The primary objective of the study is to enhance understanding of the potential clinical and ...

Detailed Description

This is a single-arm interventional study of 1000 male circumcision procedures using the ShangRing device. The primary objective of the study is to enhance understanding of the potential clinical and ...

Eligibility Criteria

Inclusion

  • Male, 13 years old and above
  • Agrees to return to the facility where circumcision procedure is done for device removal on day 7 and to have home or off-site visits if deemed necessary by the ShangRing™ providers
  • Is able and willing to provide a valid physical address of residence and at least one alternate address (address of employer, school, or friend/relative) for tracing
  • Is able and willing to provide a valid primary phone number and at least one alternate phone number (phone number of friend/relative) and agrees to be contacted via that alternate number and person. This will facilitate telephone-based follow-up should he not return for the scheduled post-removal follow-up visits.

Exclusion

  • Males below 13 years of age
  • Males for whom the correct fitting size of ShangRing™ Device is not available
  • Anatomical abnormalities including adhesions
  • Cognitive impairment
  • Any health condition (reported or observed) that ShangRing™ providers deem a contraindication to the procedure. These may include history of diabetes, peripheral vascular disease, cancer, bleeding disorders, and/or current moderate or severe infectious illness
  • HIV - positive (although may still undergo surgical circumcision)
  • Anatomical variations and anomalies of genitalia
  • Hypospadias, epispadias, or other urethral anomaly
  • Hydrocele
  • Scrotal hernia
  • Other genital anomaly or disease including infectious or traumatic ulcers
  • Dermatitis of the penis or foreskin
  • Genital warts
  • Urethral discharge
  • Balanitis

Key Trial Info

Start Date :

November 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 30 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03761836

Start Date

November 1 2020

End Date

December 30 2021

Last Update

December 22 2020

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Matola II Health Center

Matola, Maputo Province, Mozambique

2

September 17 Health Center

Quelimane, Zambezia Province, Mozambique

3

Infulene Psychiatric Hospital

Maputo, Mozambique